Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.

Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, Fewlass C, Watts M, Hessel C, Cordova J, Glezen WP.

Vaccine. 2005 Feb 18;23(13):1540-8.

PMID:
15694506
2.

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.

Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.

Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.

PMID:
17698577
3.

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.

Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, Fewlass C, Halloran ME, Longini IM Jr, Glezen WP.

Arch Pediatr Adolesc Med. 2004 Jan;158(1):65-73.

PMID:
14706961
4.

Herd protection against influenza.

Glezen WP.

J Clin Virol. 2006 Dec;37(4):237-43. Epub 2006 Sep 26. Review.

PMID:
17008123
5.

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.

Halloran ME, Piedra PA, Longini IM Jr, Gaglani MJ, Schmotzer B, Fewlass C, Herschler GB, Glezen WP.

Vaccine. 2007 May 16;25(20):4038-45. Epub 2007 Mar 12.

6.

Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures.

Halloran ME, Longini IM Jr, Gaglani MJ, Piedra PA, Chu H, Herschler GB, Glezen WP.

Am J Epidemiol. 2003 Aug 15;158(4):305-11.

PMID:
12915495
7.

Role of influenza vaccine for healthy children in the US.

Block SL.

Paediatr Drugs. 2004;6(4):199-209. Review.

PMID:
15339199
8.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group..

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
9.
10.

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.

Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB.

Pediatrics. 2002 Oct;110(4):662-72.

PMID:
12359778
11.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

12.

Universal influenza vaccination and live attenuated influenza vaccination of children.

Glezen WP.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S104-9. doi: 10.1097/INF.0b013e318168b729.

PMID:
18820568
13.

Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.

Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD; CAIV-T Study Group..

Pediatr Infect Dis J. 2006 Oct;25(10):870-9.

PMID:
17006279
14.

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.

Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM.

Pediatr Infect Dis J. 2004 Feb;23(2):138-44.

PMID:
14872180
15.

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.

Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network..

Pediatr Infect Dis J. 2007 Jul;26(7):619-28.

PMID:
17596805
16.

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.

Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, Hessel C, Cho I, Mendelman PM.

Clin Infect Dis. 2004 Oct 1;39(7):920-7. Epub 2004 Sep 7.

PMID:
15472840
17.

Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.

Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R; Cold-Adapted, Trivalent, Influenza Vaccine Study Group..

Pediatr Infect Dis J. 2003 Jan;22(1):28-34.

PMID:
12544405
18.

Immunization against viral respiratory disease: a review.

Greenberg HB, Piedra PA.

Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S254-61. Review.

PMID:
15577581
19.

Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.

Belshe RB, Mendelman PM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):745-67. Review.

PMID:
14753390
20.

Cold-adapted, live attenuated influenza vaccine.

Glezen WP.

Expert Rev Vaccines. 2004 Apr;3(2):131-9. Review.

PMID:
15056039

Supplemental Content

Support Center